Učitavanje...
Role of PCSK9 Inhibitors in Patients with Familial Hypercholesterolemia
Patients with familial hypercholesterolemia (FH) are at high or very high risk for cardiovascular disease. Those with heterozygous FH (HeFH) often do not reach low-density lipoprotein cholesterol (LDL-C) targets with statin and ezetimibe therapy, and those with homozygous FH (HoFH) usually require a...
Spremljeno u:
| Izdano u: | Endocrinol Metab (Seoul) |
|---|---|
| Glavni autori: | , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Korean Endocrine Society
2021
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8090480/ https://ncbi.nlm.nih.gov/pubmed/33866776 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3803/EnM.2021.964 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|